Changing incidence of serum 25-hydroxyvitamin d values above 50 ng/mL: A 10-year population-based study

Daniel V. Dudenkov, Barbara P. Yawn, Sara S. Oberhelman, Philip R. Fischer, Ravinder Jit Singh, Stephen S. Cha, Julie A. Maxson, Stephanie M. Quigg, Tom D. Thacher

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective To determine the incidence trend of 25-hydroxyvitamin D (25(OH)D) values above 50 ng/mL and associated toxicity. Patients and Methods We conducted a retrospective population-based study in Olmsted County, Minnesota, in the 10-year period from January 1, 2002, through December 31, 2011, by using the Rochester Epidemiology Project. Individuals were eligible if they resided in Olmsted County during the study period and had a measured 25(OH)D value above 50 ng/mL. The date of the first 25(OH)D value above 50 ng/mL was considered the index date for incidence determination. Hypercalcemia, the primary vitamin D toxicity, was considered potentially associated with the 25(OH)D concentration if it was measured within 3 months of the 25(OH)D measurement, and such cases had a medical record review. Results Of 20,308 total 25(OH)D measurements, 1714 (8.4%), 123 (0.6%), and 37 (0.2%) unique persons had 25(OH)D values above 50, 80 and above, and 100 ng/mL and above, respectively. The age- and sex-adjusted incidence of 25(OH)D values above 50 ng/mL increased from 9 to 233 cases per 100,000 person-years from 2002 to 2011 (P<.001), respectively, and was greatest in persons aged 65 years and older (P<.001) and in women (P<.001). Serum 25(OH)D values were not significantly related to serum calcium values (P=.20) or with the risk of hypercalcemia (P=.24). A medical record review identified 4 cases (0.2%) in whom 25(OH)D values above 50 ng/mL were temporally associated with hypercalcemia, but only 1 case had clinical toxicity associated with the highest observed 25(OH)D value of 364 ng/mL. Conclusion The incidence of 25(OH)D values above 50 ng/mL increased significantly between 2002 and 2011 without a corresponding increase in acute clinical toxicity.

Original languageEnglish (US)
Pages (from-to)577-586
Number of pages10
JournalMayo Clinic Proceedings
Volume90
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

antineoplaston A10
Hypercalcemia
Incidence
Serum
Population
Medical Records
Vitamin D
Epidemiology
Calcium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dudenkov, D. V., Yawn, B. P., Oberhelman, S. S., Fischer, P. R., Singh, R. J., Cha, S. S., ... Thacher, T. D. (2015). Changing incidence of serum 25-hydroxyvitamin d values above 50 ng/mL: A 10-year population-based study. Mayo Clinic Proceedings, 90(5), 577-586. https://doi.org/10.1016/j.mayocp.2015.02.012

Changing incidence of serum 25-hydroxyvitamin d values above 50 ng/mL : A 10-year population-based study. / Dudenkov, Daniel V.; Yawn, Barbara P.; Oberhelman, Sara S.; Fischer, Philip R.; Singh, Ravinder Jit; Cha, Stephen S.; Maxson, Julie A.; Quigg, Stephanie M.; Thacher, Tom D.

In: Mayo Clinic Proceedings, Vol. 90, No. 5, 01.05.2015, p. 577-586.

Research output: Contribution to journalArticle

Dudenkov, DV, Yawn, BP, Oberhelman, SS, Fischer, PR, Singh, RJ, Cha, SS, Maxson, JA, Quigg, SM & Thacher, TD 2015, 'Changing incidence of serum 25-hydroxyvitamin d values above 50 ng/mL: A 10-year population-based study', Mayo Clinic Proceedings, vol. 90, no. 5, pp. 577-586. https://doi.org/10.1016/j.mayocp.2015.02.012
Dudenkov, Daniel V. ; Yawn, Barbara P. ; Oberhelman, Sara S. ; Fischer, Philip R. ; Singh, Ravinder Jit ; Cha, Stephen S. ; Maxson, Julie A. ; Quigg, Stephanie M. ; Thacher, Tom D. / Changing incidence of serum 25-hydroxyvitamin d values above 50 ng/mL : A 10-year population-based study. In: Mayo Clinic Proceedings. 2015 ; Vol. 90, No. 5. pp. 577-586.
@article{4964369282914f12a98832c9890e968b,
title = "Changing incidence of serum 25-hydroxyvitamin d values above 50 ng/mL: A 10-year population-based study",
abstract = "Objective To determine the incidence trend of 25-hydroxyvitamin D (25(OH)D) values above 50 ng/mL and associated toxicity. Patients and Methods We conducted a retrospective population-based study in Olmsted County, Minnesota, in the 10-year period from January 1, 2002, through December 31, 2011, by using the Rochester Epidemiology Project. Individuals were eligible if they resided in Olmsted County during the study period and had a measured 25(OH)D value above 50 ng/mL. The date of the first 25(OH)D value above 50 ng/mL was considered the index date for incidence determination. Hypercalcemia, the primary vitamin D toxicity, was considered potentially associated with the 25(OH)D concentration if it was measured within 3 months of the 25(OH)D measurement, and such cases had a medical record review. Results Of 20,308 total 25(OH)D measurements, 1714 (8.4{\%}), 123 (0.6{\%}), and 37 (0.2{\%}) unique persons had 25(OH)D values above 50, 80 and above, and 100 ng/mL and above, respectively. The age- and sex-adjusted incidence of 25(OH)D values above 50 ng/mL increased from 9 to 233 cases per 100,000 person-years from 2002 to 2011 (P<.001), respectively, and was greatest in persons aged 65 years and older (P<.001) and in women (P<.001). Serum 25(OH)D values were not significantly related to serum calcium values (P=.20) or with the risk of hypercalcemia (P=.24). A medical record review identified 4 cases (0.2{\%}) in whom 25(OH)D values above 50 ng/mL were temporally associated with hypercalcemia, but only 1 case had clinical toxicity associated with the highest observed 25(OH)D value of 364 ng/mL. Conclusion The incidence of 25(OH)D values above 50 ng/mL increased significantly between 2002 and 2011 without a corresponding increase in acute clinical toxicity.",
author = "Dudenkov, {Daniel V.} and Yawn, {Barbara P.} and Oberhelman, {Sara S.} and Fischer, {Philip R.} and Singh, {Ravinder Jit} and Cha, {Stephen S.} and Maxson, {Julie A.} and Quigg, {Stephanie M.} and Thacher, {Tom D.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.mayocp.2015.02.012",
language = "English (US)",
volume = "90",
pages = "577--586",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - Changing incidence of serum 25-hydroxyvitamin d values above 50 ng/mL

T2 - A 10-year population-based study

AU - Dudenkov, Daniel V.

AU - Yawn, Barbara P.

AU - Oberhelman, Sara S.

AU - Fischer, Philip R.

AU - Singh, Ravinder Jit

AU - Cha, Stephen S.

AU - Maxson, Julie A.

AU - Quigg, Stephanie M.

AU - Thacher, Tom D.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Objective To determine the incidence trend of 25-hydroxyvitamin D (25(OH)D) values above 50 ng/mL and associated toxicity. Patients and Methods We conducted a retrospective population-based study in Olmsted County, Minnesota, in the 10-year period from January 1, 2002, through December 31, 2011, by using the Rochester Epidemiology Project. Individuals were eligible if they resided in Olmsted County during the study period and had a measured 25(OH)D value above 50 ng/mL. The date of the first 25(OH)D value above 50 ng/mL was considered the index date for incidence determination. Hypercalcemia, the primary vitamin D toxicity, was considered potentially associated with the 25(OH)D concentration if it was measured within 3 months of the 25(OH)D measurement, and such cases had a medical record review. Results Of 20,308 total 25(OH)D measurements, 1714 (8.4%), 123 (0.6%), and 37 (0.2%) unique persons had 25(OH)D values above 50, 80 and above, and 100 ng/mL and above, respectively. The age- and sex-adjusted incidence of 25(OH)D values above 50 ng/mL increased from 9 to 233 cases per 100,000 person-years from 2002 to 2011 (P<.001), respectively, and was greatest in persons aged 65 years and older (P<.001) and in women (P<.001). Serum 25(OH)D values were not significantly related to serum calcium values (P=.20) or with the risk of hypercalcemia (P=.24). A medical record review identified 4 cases (0.2%) in whom 25(OH)D values above 50 ng/mL were temporally associated with hypercalcemia, but only 1 case had clinical toxicity associated with the highest observed 25(OH)D value of 364 ng/mL. Conclusion The incidence of 25(OH)D values above 50 ng/mL increased significantly between 2002 and 2011 without a corresponding increase in acute clinical toxicity.

AB - Objective To determine the incidence trend of 25-hydroxyvitamin D (25(OH)D) values above 50 ng/mL and associated toxicity. Patients and Methods We conducted a retrospective population-based study in Olmsted County, Minnesota, in the 10-year period from January 1, 2002, through December 31, 2011, by using the Rochester Epidemiology Project. Individuals were eligible if they resided in Olmsted County during the study period and had a measured 25(OH)D value above 50 ng/mL. The date of the first 25(OH)D value above 50 ng/mL was considered the index date for incidence determination. Hypercalcemia, the primary vitamin D toxicity, was considered potentially associated with the 25(OH)D concentration if it was measured within 3 months of the 25(OH)D measurement, and such cases had a medical record review. Results Of 20,308 total 25(OH)D measurements, 1714 (8.4%), 123 (0.6%), and 37 (0.2%) unique persons had 25(OH)D values above 50, 80 and above, and 100 ng/mL and above, respectively. The age- and sex-adjusted incidence of 25(OH)D values above 50 ng/mL increased from 9 to 233 cases per 100,000 person-years from 2002 to 2011 (P<.001), respectively, and was greatest in persons aged 65 years and older (P<.001) and in women (P<.001). Serum 25(OH)D values were not significantly related to serum calcium values (P=.20) or with the risk of hypercalcemia (P=.24). A medical record review identified 4 cases (0.2%) in whom 25(OH)D values above 50 ng/mL were temporally associated with hypercalcemia, but only 1 case had clinical toxicity associated with the highest observed 25(OH)D value of 364 ng/mL. Conclusion The incidence of 25(OH)D values above 50 ng/mL increased significantly between 2002 and 2011 without a corresponding increase in acute clinical toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84929471022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929471022&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2015.02.012

DO - 10.1016/j.mayocp.2015.02.012

M3 - Article

C2 - 25939935

AN - SCOPUS:84929471022

VL - 90

SP - 577

EP - 586

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -